At Abiozen, we redefine sterile API production through a comprehensive, technologically advanced framework that prioritizes precision, consistency, and regulatory excellence. Our capabilities span a broad spectrum of active pharmaceutical ingredients—ranging from high-purity small molecules to complex biologics and biosimilars, potent oncology APIs, and specialty injectables tailored for rare and hormonal therapies. Each category is supported by state-of-the-art infrastructure, including ISO Class 5 cleanrooms, automated synthesis and fill-finish platforms, and robust analytical testing systems that ensure product sterility and integrity at every stage.

Abiozen’s Small Molecule APIs are synthesized with stereochemical precision and optimized for yield and reproducibility, supporting therapeutic areas such as cardiovascular health, metabolic disorders, and infectious diseases. In Biologics and Biosimilars, we leverage high-efficiency cell culture systems and single-use bioreactors to produce antibodies and therapeutic proteins with titers up to 10 g/L. Our Oncology and Critical Care APIs are manufactured in containment-controlled environments, enabling safe handling of HPAPIs and immunotherapy agents. For Hormonal and Specialty Injectables, we deliver advanced formulations—including peptides and lipid-based delivery systems—with stringent control over particle size and polymorphic forms.

Inspired by industry leaders like Curia Global and Thermo Fisher, Abiozen delivers sterile APIs with unmatched quality, scalability, and compliance—empowering global pharmaceutical innovation.